PURPOSE: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancer patients. METHODS: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. RESULTS: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86%) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95% CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. CONCLUSIONS: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.
PURPOSE: We investigated the association between serum levels of 25-hydroxyvitamin D (25-OHD) and risk of death in Norwegian cancerpatients. METHODS: The study population was 658 patients with cancers of the breast (n = 251), colon (n = 52), lung (n = 210), and lymphoma (n = 145), obtained from JANUS, a population-based serum bank in Norway. Serum samples were collected within 90 days of cancer diagnosis and were analyzed for 25-OHD. Patients were diagnosed during 1984-2004 and were followed for death throughout 2008. We used Cox regression models to assess the relationship between serum 25-OHD and risk of death. RESULTS: Three hundred and ninety-nine patients died during follow-up, of whom 343 (86%) died from cancer. Adjusted for sex, age at diagnosis, and season of blood sampling, patients with 25-OHD levels below 46 nmol/L at diagnosis experienced shorter survival. Compared to patients in the lowest quartile of serum 25-OHD, the risk of cancer death among patients in the highest quartile was significantly reduced (HR 0.36 95% CI 0.27, 0.51). The estimated change in risk of cancer death was most pronounced between the first and the second quartile. The associations between 25-OHD levels and survival were observed for all four cancers. CONCLUSIONS: Higher circulating serum levels of 25-OHD were positively associated with the survival for cancers of the breast, colon, lung, and lymphoma.
Authors: Jonathan N Hofmann; Kai Yu; Ronald L Horst; Richard B Hayes; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Matthew T Drake; Matthew J Maurer; Brian K Link; Thomas M Habermann; Stephen M Ansell; Ivana N Micallef; Jennifer L Kelly; William R Macon; Grzegorz S Nowakowski; David J Inwards; Patrick B Johnston; Ravinder J Singh; Cristine Allmer; Susan L Slager; George J Weiner; Thomas E Witzig; James R Cerhan Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: M K Shea; E J Benjamin; J Dupuis; J M Massaro; P F Jacques; R B D'Agostino; J M Ordovas; C J O'Donnell; B Dawson-Hughes; R S Vasan; S L Booth Journal: Eur J Clin Nutr Date: 2007-11-21 Impact factor: 4.016
Authors: Johanna E Torfadottir; Thor Aspelund; Unnur A Valdimarsdottir; Mary Frances Cotch; Laufey Tryggvadottir; Tamara B Harris; Vilmundur Gudnason; Hans-Olov Adami; Lorelei A Mucci; Edward L Giovannucci; Meir J Stampfer; Laufey Steingrimsdottir Journal: Cancer Causes Control Date: 2019-02-25 Impact factor: 2.506
Authors: Kimmie Ng; Jamil B Scott; Bettina F Drake; Andrew T Chan; Bruce W Hollis; Paulette D Chandler; Gary G Bennett; Edward L Giovannucci; Elizabeth Gonzalez-Suarez; Jeffrey A Meyerhardt; Karen M Emmons; Charles S Fuchs Journal: Am J Clin Nutr Date: 2013-12-24 Impact factor: 7.045
Authors: Song Yao; Stephen A Haddad; Qiang Hu; Song Liu; Kathryn L Lunetta; Edward A Ruiz-Narvaez; Chi-Chen Hong; Qianqian Zhu; Lara Sucheston-Campbell; Ting-Yuan David Cheng; Jeannette T Bensen; Candace S Johnson; Donald L Trump; Christopher A Haiman; Andrew F Olshan; Julie R Palmer; Christine B Ambrosone Journal: Int J Cancer Date: 2015-12-28 Impact factor: 7.396
Authors: Vladislava T Djurasinović; Biljana S Mihaljević; Sandra B Šipetić Grujičić; Svetlana D Ignjatović; Goran Trajković; Milena R Todorović-Balint; Darko A Antić; Jelena S Bila; Boško M Andjelić; Jelena J Jeličić; Vojin M Vuković; Aleksandra M Nikolic; Stanislaw Klek Journal: Support Care Cancer Date: 2018-03-06 Impact factor: 3.603
Authors: Akiko Chiba; Rachna Raman; Alexandra Thomas; Pierre-Jean Lamy; Marie Viala; Stephane Pouderoux; Sarah L Mott; Mary C Schroeder; Simon Thezenas; William Jacot Journal: Clin Breast Cancer Date: 2017-12-11 Impact factor: 3.225